Results
pleural effusion, mitral valve replacement, anemia, pericardial effusion, atrial fibrillation, aortic valve replacement
PLEURAL EFFUSION, ADVERSE EVENTS, MSSA COLONIZATION, ANEMIA, PERICARDIAL EFFUSION, ATRIAL FIBRILLATION
Patients were recruited in the countries of Georgia (89.2%, 9 centers), Serbia (7.2%, 2 centers), and the United State (3.6%, 2 centers). Most of these patients were male (75.9%). The most common surgeries were coronary artery bypass graft (63.8%), mitral valve replacement and/or repair (16.9%), and aortic valve replacement (16.9%). A foreign implant was placed in 39.8% of patients in the micro-ITT primary efficacy set; 100% of patients received all 5 doses. MSSA colonization occurred in 96.8% of patients, and 3.2% had MRSA.The baseline nasal 
Change in burden of nasal Within 1 hour of incision closure, the decrease in When assessing the percentage of patients exhibiting zero nasal 
Percentage of patients with zero nasal No SSIs were identified during the study or follow-up periods of 1 month or 3 months (for those with a foreign implant). Overall, 95.2% of patients received prophylactic skin decolonization preoperatively.No treatment-emergent adverse events (TEAEs), laboratory or other safety findings were considered related to either arm in the 124 patients evaluated as the safety population. In the XF-73 and placebo groups, respectively, the most frequently reported TEAEs were pleural effusion (16 and 14 patients), anemia (5 and 6 patients), pericardial effusion (5 and 5 patients), and atrial fibrillation (5 and 4 patients).No local reactions at the application site (ie, anterior nares) occurred according to an ENT specialist and there were no significant changes to sense of smell (B-SIT) during the study.